» Articles » PMID: 23553345

Aggregate Versus Day Level Association Between Methamphetamine Use and HIV Medication Non-adherence Among Gay and Bisexual Men

Overview
Journal AIDS Behav
Date 2013 Apr 5
PMID 23553345
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Methamphetamine use is associated with HIV infection, especially among gay and bisexual men. Methamphetamine use contributes to disease progression both directly, by increasing viral load and damaging the immune system, and indirectly, by decreasing medication adherence. Research examining the association of methamphetamine use and non-adherence has traditionally compared groups of users and nonusers on adherence, compared methamphetamine use between participants above or below some threshold level of adherence (e.g. >90 % dose adherence), or examined aggregate relationships. Using Timeline Follow-back procedures, the present study examined aggregate, threshold, and day-level associations of methamphetamine use with non-adherence in 210 HIV-positive gay and bisexual methamphetamine-using men. Methamphetamine use was not associated with adherence behavior at the aggregate-level, but methamphetamine use on a given day was associated with 2.3 times the odds of non-adherence on that day. Threshold results were equivocal. These data suggest that the methamphetamine and non-adherence relationship is complicated: non-adherence is more likely to occur on days in which methamphetamine is used, but participants reported more non-adherence days in which methamphetamine was not used. This seeming paradox generates questions about the selection of analytical techniques and has important implications for behavioral interventions targeting substance use and adherence among HIV-positive individuals.

Citing Articles

Alcohol and drug use severity are independently associated with antiretroviral adherence in the current treatment era.

Ma J, Luu B, Ruderman S, Whitney B, Merrill J, Mixson L AIDS Care. 2023; 36(5):618-630.

PMID: 37419138 PMC: 10771542. DOI: 10.1080/09540121.2023.2223899.


Modelling the impact of protein-kinase R allelic variant on HIV biomarkers trajectories by means of latent class mixed models.

Brombin C, Bagaglio S, Cugnata F, Castagna A, Uberti-Foppa C, Salpietro S Sci Rep. 2022; 12(1):18575.

PMID: 36329104 PMC: 9633692. DOI: 10.1038/s41598-022-23289-4.


Leukocyte telomere length is not shortened in methamphetamine dependence or methamphetamine-induced psychosis but is increased following traumatic events.

Rungnirundorn T, Krusong K, Kalayasiri R, Maes M World J Biol Psychiatry. 2021; 23(8):613-621.

PMID: 34895035 PMC: 9991870. DOI: 10.1080/15622975.2021.2016957.


Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use.

Truong H, Fatch R, Deeks S, Krone M, Martin J, Hunt P Curr HIV Res. 2021; 19(6):497-503.

PMID: 34176462 PMC: 10659984. DOI: 10.2174/1570162X19666210625103902.


Recreational Drug Use in People Living with HIV in Spain: Factors Associated with Drug Use and the Impact on Clinical Outcomes.

Castro-Granell V, Garin N, Jaen A, Casado J, Leal L, Cenoz S AIDS Behav. 2021; 25(12):3883-3897.

PMID: 33932187 PMC: 8602223. DOI: 10.1007/s10461-021-03271-3.


References
1.
Montaner J . Treatment as prevention--a double hat-trick. Lancet. 2011; 378(9787):208-9. DOI: 10.1016/S0140-6736(11)60821-0. View

2.
Palombi L, Marazzi M, Guidotti G, Germano P, Buonomo E, Scarcella P . Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis. 2010; 48(1):115-122. DOI: 10.1086/593312. View

3.
Roll J, Petry N, Stitzer M, Brecht M, Peirce J, McCann M . Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry. 2006; 163(11):1993-9. DOI: 10.1176/ajp.2006.163.11.1993. View

4.
Gorbach P, Drumright L, Javanbakht M, Pond S, Woelk C, Daar E . Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2008; 47(5):639-43. PMC: 4153748. DOI: 10.1097/QAI.0b013e3181684c3d. View

5.
Colfax G, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht F . Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS. 2007; 21(2):239-41. DOI: 10.1097/QAD.0b013e3280114a29. View